Journal article
Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs
PL van der Peet, C Gunawan, A Abdul-Ridha, S Ma, DJ Scott, AL Gundlach, RAD Bathgate, JM White, SJ Williams
Methodsx | ELSEVIER | Published : 2018
Abstract
Chemogenetics uses engineered proteins that are controlled by small molecule actuators, allowing in vivo functional studies of proteins with temporal and dose control, and include Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). One major class of DREADDs are mutated muscarinic receptors that are unresponsive to acetylcholine, and are activated by administration of clozapine N-oxide (CNO). However, CNO is available in only small amounts and large scale studies involving animals and multiple cohorts are prohibitively expensive for many investigators. The precursor, clozapine, is also expensive when purchased from specialist suppliers. Here we report: • A simple extraction..
View full abstractGrants
Funding Acknowledgements
We thank the Australian Research Council and the National Health and Medical Research Council (NHMRC) Australia for grant support. We thank Dr. Sebastian Marcuccio (Advanced Molecular Technologies) for helpful discussions, and Prof. Arthur Christopoulos (Monash Institute for Pharmaceutical Sciences) for providing the FlpIn CHO M<INF>1</INF> DREADD cell line. A.A. is an NHMRC-ARC Dementia Research Development Fellow and R.A.D.B. is an NHMRC Senior Research Fellow. Studies at The Florey were supported by the Victorian Government Operational Infrastructure Support Program.